TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01605357
Drug: Induced, sustained hypernatremia using hypertonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the experimental arm will receive hypertonic saline to target a serum sodium goal of 150 - 160 mmol/L. All hypertonic saline will be administered intravenously.~Loading phase: Upon enrollment 23.4 % hypertonic saline (volume 20 cc) will be administered via a central venous catheter. A continuous infusion of 3% hypertonic saline will be administered at a rate of 30 cc per hour and titrated every six hours to target a serum sodium goal of 150-160 mmol/L.~Maintenance phase: Titrate serum sodium to 150-160 mmol/L using continuous 3% hypertonic saline infusion.~Discontinuation phase: After 5 days of completed therapy, begin to wean 3% hypertonic saline rate by 10cc every 6 hours. Discontinue hypertonic saline infusion after infusing at a rate of 20cc an hour for 6 hours.~Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines
Study: NCT01605357
Drug: Standard of care (hypertonic saline and mannitol; serum sodium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines. Hyponatremia ( serum sodium \< 135 mmol/L) is to be corrected at the discretion of the provider.
Study: NCT03554018
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500-1000mg every 6 hours
Study: NCT03554018
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 600mg every 6 hours
Study: NCT03554018
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: To match acetaminophen, patients will take one or two capsules every 6 hours
Study: NCT01154452
Drug: Gamma-Secretase Inhibitor RO4929097
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00587483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT02908581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT02908581
Drug: Iron 150 mg and Folic acid 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron will be administered with folic acid orally
Study: NCT01027429
Drug: procaine penicillin and gentamicin
Normalized name: Penicillin G Procaine
DrugBank: Procaine benzylpenicillin (DB09320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days
Study: NCT01027429
Drug: amoxicillin and gentamicin
Normalized name: vonoprazan and amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days
Study: NCT01027429
Drug: procaine penicillin, gentamicin, amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
Study: NCT01471821
Drug: antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiretroviral treatment
Study: NCT00971282
Drug: adapalen 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-individual (split-face) comparison: Differin® 0.1% (whole face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits.
Study: NCT00670930
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00200967
Drug: beclomethasone HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mcg beclomethasone HFA (QVAR, Teva Pharmaceutical Industries)
Study: NCT01790607
Drug: ONO-2745 /CNS 7056
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01444430
Drug: Symbicort pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were randomized to Symbicort and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): Symbicort pMDI 80/4.5 μg x 2 actuations bid (morning and evening) or Symbicort pMDI 160/4.5 μg x 2 actuations bid (morning and evening), for oral inhalation.
Study: NCT02453555
Drug: Empa + lina highdose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03468322
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle-only control study medication is the same formulation as investigational product without active ingredient
Study: NCT00205816
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00331032
Drug: 3% w/w SPL7013 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.
Study: NCT00331032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.
Study: NCT03794557
Drug: PUL-042 Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUL-042 Inhalation Solution
Study: NCT02250976
Drug: Livasupril Cap.160/2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate pellet( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
Study: NCT02250976
Drug: Lipilfen cap. 160mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate 160mg
Study: NCT02250976
Drug: Livaro tab. 2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin Ca 2mg
Study: NCT00376636
Drug: SPP635 (drug)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01146613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical matched placebo x 2, 2xday, 13 weeks
Study: NCT02217618
Drug: LY2409021
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00538057
Drug: GW685698X & GW642444M
Approvals — FDA: no, EMA: no, PMDA: no
Description: study drug
Study: NCT04023292
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
Study: NCT04023292
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
Study: NCT00441766
Drug: AGN 203818
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks
Study: NCT00441766
Drug: AGN 203818
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks
Study: NCT00441766
Drug: AGN 203818
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks
Study: NCT00441766
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: placebo capsule every 12 hours for 4 weeks
Study: NCT04460183
Drug: RESP301, a Nitric Oxide generating solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product application requires inhalation using a standard handheld nebulizer.
Study: NCT00225914
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
Study: NCT04593121
Drug: BIIB107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT04593121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT03985280
Drug: Intraaticular steroids and local anesthetic injections
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraaticular steroids and local anesthetic injections
Study: NCT01132703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the Treatment Arm.
Study: NCT01119443
Drug: PPX ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPX ER 0.375mg - 1.5mg for 32 days totally
Study: NCT01201551
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week1, day1: 1 eyedrop/left eye Week1, day2: 2 eyedrops/left eye Week2, day1: 1 eyedrop/right eye Week2, day2: 2 eyedrops/right eye
Study: NCT04157699
Drug: TDF tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF tablet 300mg QD
Study: NCT04157699
Drug: QL-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL-007 tablet
Study: NCT00439335
Drug: Placebo (IM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be 0.1 mL of saline administered by the IM route.
Study: NCT00439335
Drug: Placebo (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be 0.1 mL of saline administered by the ID route.
Study: NCT01144143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the placebo will be injected into the joint through a needle
Study: NCT01144143
Drug: Standard of Care: Methylprednisolone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone acetate will be injected into the joint through a needle
Study: NCT00263003
Drug: Irbesartan/hydrochlorothiazide
Normalized name: irbesartan/hydrochlorothiazide 300 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00512278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00753948
Drug: N-Nitro L-arginine-methylester (L-NAME)
Normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A non-specific inhibitor of the nitric oxide synthase enzyme.
Study: NCT02345616
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02491281
Drug: LNA043
Approvals — FDA: no, EMA: no, PMDA: no
Description: ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
Study: NCT02491281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
Study: NCT01452477
Drug: tanshinone placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
Study: NCT00609752
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard treatment regimens based on body weight will be used (approximately 2 mg per kg), with a stepwise dose reduction over a 10-14 week period.
Study: NCT02639247
Drug: SOF/VEL/VOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100/100 mg FDC tablet administered orally once daily with food
Study: NCT02639247
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg FDC tablet administered orally once daily without regard to food
Study: NCT03045887
Drug: GSK2292767 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation
Study: NCT03045887
Drug: GSK2292767 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation
Study: NCT03045887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose as powder for inhalation
Study: NCT02862977
Drug: ketoprofen and cyclobenzaprine association with caffeine
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h
Study: NCT02862977
Drug: Cyclobenzaprine with caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will take 2 tablets (combination of cyclobenzaprine and caffeine), oral, per day, each 12h
Study: NCT03294395
Drug: Gentamicin Sulfate, Injectable
Normalized name: Gentamicin Sulfate, Injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose 5mg/kg (maximum 400mg) intramuscular injection
Study: NCT01913847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo TID for 12 weeks
Study: NCT03368196
Drug: DS-8201a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: An antibody drug conjugate
Study: NCT01118780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by mouth, daily for 10 weeks
Study: NCT00870480
Drug: Proscar® 5 mg Tablet, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fasting conditions
Study: NCT02864264
Drug: Placebo matching BMS-986184
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00705874
Drug: CGC-11047 and 5-flurouracil / leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
Study: NCT02326727
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: General Anesthesia
Study: NCT02719392
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline is an FDA-approved antibiotic commonly used to treat bacterial infections.
Study: NCT04283006
Drug: CD20/CD22 dual Targeted CAR T-cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject receive CD20/CD22 dual Targeted CAR T-cells by intravenous infusion
Study: NCT01406600
Drug: recombinant hCG (Ovidrel®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24\~48 hours from optimal ovarian stimulation status.
Study: NCT00533429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, daily
Study: NCT03809273
Drug: Yangxinshi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangxinshi pill 3 pills /tid
Study: NCT02592421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT02553187
Drug: Kanglaite Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL, slow IV drip, once daily for 14 consecutive days, subsequent courses repeated after a 7-day interval.~Subjects will be treated for 4 courses (12 weeks).
Study: NCT03506620
Drug: Saline Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 cc of saline will be injected in the form of a QL block as a placebo.
Study: NCT00509327
Drug: glucosemonohydricum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
Study: NCT00300378
Drug: desvenlafaxine 50 mg
Normalized name: desvenlafaxine 50 MG
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00300378
Drug: desvenlafaxine 100 mg
Normalized name: desvenlafaxine 100 MG
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02710188
Drug: HTL0009936 modified release
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTL0009936 modified release
Study: NCT02710188
Drug: HTL0009936 immediate release
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTL0009936 immediate release
Study: NCT00803361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules, oral, once a day for 15 weeks
Study: NCT01694004
Drug: Benzocaine Infusion into Duodenum
Normalized name: Sus scrofa duodenum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02020590
Drug: ALLOB® implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.
Study: NCT03521791
Drug: PRO-155
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO-155 (Zebesten ofteno®) Active agent: bromfenac 0.90 mg / mL, dropper bottle of low density polyethylene for multidose administration in the form of an ophthalmic solution of 5 mL (milliliters). Sanitary registry in Mexico: 108M2014~Sodium hyaluronate 0.4% \[Lagricel ofteno®\] 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac
Study: NCT01122979
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
Study: NCT01186250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo taken daily for one year
Study: NCT02273102
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.
Study: NCT01655186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01022970
Drug: QAX576 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01022970
Drug: QAX576
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03965182
Drug: PEG plus SPMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: one sachet of PEG and one sachet will be administered as the bowel prep regimen
Study: NCT03965182
Drug: SPMC
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 sachets will be administered as the bowel prep regimen.
Study: NCT02706925
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00600067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsules, once daily, 28 weeks
Study: NCT02132897
Drug: Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine CR Tablets 400 milligrams is given orally with 250 mL of water at room temperature.
Study: NCT02564588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT01224236
Drug: Iron Supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg/day elemental iron as multivitamin with iron solution
Study: NCT01842373
Drug: BLT
Normalized name: BLT-25
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00932074
Drug: KP-413 Ointment
Normalized name: Draxxin KP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
Study: NCT00570713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per package insert.
Study: NCT01600404
Drug: antimuscarinic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01781377
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SALINE INFUSION
Study: NCT01462929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: Dry powder Route of administration: Oral inhalation by Genuair multidose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) AND Oral inhalation by HandiHaler single-dose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h).
Study: NCT03240562
Drug: patient controlled analgesia
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: two groups have same intravenous patient controlled analgesia
Study: NCT01583114
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: form:1 tablet contained 5 mg placebo; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
Study: NCT04481607
Drug: TQB3454
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3454 tablets is a small molecule oral drug.
Study: NCT02554799
Drug: MMV390048 formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMV390048 formulation B, tablet
Study: NCT01820806
Drug: 100 mg dose of [14C] GLPG0634
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed with a single oral 100 mg dose of \[14C\] GLPG0634 on one occasion
Study: NCT00977483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet once daily 4 years double-blind treatment period
Study: NCT02250872
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg in 2 divided doses plus cisplatin
Study: NCT00287950
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01365793
Drug: 0.45% saline replacement fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10cc/Kg bolus of 0.9% saline followed by 0.45% saline used as the replacement fluid
Study: NCT01365793
Drug: 0.9% saline replacement fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10cc/Kg bolus of 0.9% saline followed by 0.9% saline used as the replacement fluid.
Study: NCT01365793
Drug: 0.45% saline intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% saline fluid
Study: NCT01365793
Drug: 0.9% saline Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline fluid
Study: NCT02808429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched to Atacicept once weekly as subcutaneous (SC) injection during this study up to a maximum of 72.1 weeks.
Study: NCT00618007
Drug: PF-00734200 30 mg QD
Normalized name: CODEINE PO4 30MG/ML (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg QD
Study: NCT00618007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01436110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
Study: NCT01847092
Drug: AZD1722
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01847092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for AZD1722